GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » E10

BIXT (Bioxytran) E10 : $-0.42 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Bioxytran's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.003. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.42 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Bioxytran was 39.30% per year. The lowest was 24.90% per year. And the median was 32.10% per year.

As of today (2024-12-14), Bioxytran's current stock price is $0.0882. Bioxytran's E10 for the quarter that ended in Sep. 2024 was $-0.42. Bioxytran's Shiller PE Ratio of today is .


Bioxytran E10 Historical Data

The historical data trend for Bioxytran's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran E10 Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.64 -17.76 -9.70 -4.39 -

Bioxytran Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.30 - -1.59 -1.53 -0.42

Competitive Comparison of Bioxytran's E10

For the Biotechnology subindustry, Bioxytran's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bioxytran's Shiller PE Ratio falls into.



Bioxytran E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bioxytran's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.003/133.0289*133.0289
=-0.003

Current CPI (Sep. 2024) = 133.0289.

Bioxytran Quarterly Data

per share eps CPI Adj_EPS
201412 6.000 99.070 8.057
201503 -0.300 99.621 -0.401
201506 -6.000 100.684 -7.928
201509 -0.073 100.392 -0.097
201512 0.000 99.792 0.000
201603 -0.600 100.470 -0.794
201606 -0.300 101.688 -0.392
201609 -0.300 101.861 -0.392
201612 0.000 101.863 0.000
201703 -0.900 102.862 -1.164
201706 -0.300 103.349 -0.386
201709 0.046 104.136 0.059
201712 -0.001 104.011 -0.001
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 -0.001 106.507 -0.001
201812 -0.003 105.998 -0.004
201903 -0.002 107.251 -0.002
201906 -0.002 108.070 -0.002
201909 -0.010 108.329 -0.012
201912 -0.010 108.420 -0.012
202003 -0.010 108.902 -0.012
202006 -0.010 108.767 -0.012
202009 -0.002 109.815 -0.002
202012 -0.010 109.897 -0.012
202103 -0.020 111.754 -0.024
202106 -0.010 114.631 -0.012
202109 -0.004 115.734 -0.005
202112 -0.010 117.630 -0.011
202203 -0.010 121.301 -0.011
202206 -0.010 125.017 -0.011
202209 -0.001 125.227 -0.001
202212 -0.010 125.222 -0.011
202303 -0.010 127.348 -0.010
202306 -0.010 128.729 -0.010
202309 -0.010 129.860 -0.010
202312 0.000 129.419 0.000
202403 -0.005 131.776 -0.005
202406 -0.004 132.554 -0.004
202409 -0.003 133.029 -0.003

Add all the adjusted EPS together and divide 10 will get our e10.


Bioxytran  (OTCPK:BIXT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Bioxytran E10 Related Terms

Thank you for viewing the detailed overview of Bioxytran's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxytran Business Description

Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Executives
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701